We are pleased to have been able to make an expeditious database release (version 2020.2), following on from our last update in March 2020 in order to make public new curation specifically related to SARS-CoV-2.
- GtoPdb now includes a new SARS-Cov-2 protein family which includes 13 members and is included under ‘anti-infective targets’ in our hierarchy
- The new targets in the SARS-CoV-2 protein family have been mapped to UniProt accessions were possible. Because so little is yet understood about SARS-CoV-2 at the molecular level, much of what is curated for these proteins has been predicted and/or extrapolated from what is known about SARS-CoV and MERS-CoV. We will of course update the pages as and when new data are published.
- Several new compounds, relevant to SARS-CoV-2 have now been added, including PRD_002214 and compound 13b (virus main protease inhibitors), otamixaban and I-432 (potential TMPRSS2 inhibitors), and β-D-N4-hydroxycytidine (a broad spectrum antiviral compound).
The Guide to Pharmacology coronavirus information page continues to be updated on a regular basis to capture the latest pharmacological strategies under investigation to mitigate against COVID-19.